Company intelligence / Profile preview
Shanghai Jiabao Yaoyin Pharmaceutical Technology
Shanghai, Shanghai, China
- Ownership
- Private
- Development stage
- Other
01
Overview
Three programs have entered clinical trials: JDB-153 (MNK x VEGFR inhibitor) has completed Phase 1 for several cancers, JDB-175 (BTK inhibitor) is in Phase 1 for lymphoma, JDB-383 (CSF-1R inhibitor) has IND approval for Giant Cell Tumor of Tendon Sheath; no topline efficacy or safety data publicly available
- Therapeutic areas
- OncologyInfectious DiseasesRheumatology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Shanghai Jiabao Yaoyin Pharmaceutical Technology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shanghai Jiabao Yaoyin Pharmaceutical Technology.